Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Moderna Therapeutics

This page shows the latest Moderna Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Moderna files record $500m IPO for RNA pipeline

Moderna files record $500m IPO for RNA pipeline

Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... Moderna’s mRNA technology attempts to turn a patient’s own

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Abbott, Allergan, Celgene, Moderna, Pfizer and Takeda feature in this month's pharma deals round-up. ... Moderna Therapeutics has received $8m of the grant to fund early-stage trials of the vaccine and plans to submit an investigational new drug

  • Deal Watch June 2016 Deal Watch June 2016

    Back to the immuno-oncology theme, near the end of June Merck &Co signed a collaboration agreement with Moderna Therapeutics to use Moderna's mRNA technology to develop personalised cancer vaccines. ... licence. 230. Moderna Therapeutics/ Merck &Co.

  • Deal Watch October 2015 Deal Watch October 2015

    Whilst considering nucleic acid-based approaches, it was interesting to see that mRNA company Moderna Therapeutics, which has a number of deals under its belt with AstraZeneca, Alexion and Merck &Co, ... This is Moderna's fourth venture in what it calls

  • Deal Watch table for January 2014 Deal Watch table for January 2014

    300. Merck/Alnylam. Divestment. Sale of Merck's RNAi therapeutics unit Sirna. 290. ... 144. Moderna Therapeutics/ Alexion Pharmaceuticals. Exclusive discovery and development. Messenger RNA (mRNA) therapeutics in rare diseases for 10 product options.

  • Deal Watch table for October 2013 Deal Watch table for October 2013

    Commercialisation.  Oralair, grass allergy sublingual tablet (pre-registration). 120. Osiris Therapeutics / Mesoblast   . ... Moderna Therapeutics / DARPA. R&D grant. mRNA therapeutics for biodefence targets (discovery).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest appointments

  • Tony de Fougerolles joins Evox Therapeutics as CEO Tony de Fougerolles joins Evox Therapeutics as CEO

    Oxford, UK-based Evox Therapeutics has appointed its new chief executive officer in the form of Tony de Fougerolles. ... Prior to this, he was chief scientific officer at Moderna Therapeutics and has held the same role at Tolerx.

  • Medicxi appoints former GSK chair Moncef Slaoui Medicxi appoints former GSK chair Moncef Slaoui

    Dr Slaoui takes on the role alongside his other board positions, which include chairman of the board at Galvani Bioelectronics, and on the boards of Artisan Biosciences, Moderna Therapeutics and Sutovax.

  • MIT chief financial officer joins Moderna Therapeutics MIT chief financial officer joins Moderna Therapeutics

    US-based biotech Moderna Therapeutics has appointed Israel Ruiz to its board of directors to serve as audit committee chair. ... Dr Noubar Afeyan, co-founder and chairman of Moderna Therapeutics, said: “We are delighted to welcome Israel to Moderna's

  • PureTech Health appoints chief scientific officer PureTech Health appoints chief scientific officer

    Bringing over 30 years of clinical development experience to the role, he joins from Moderna Therapeutics where he most recently served as president and chief scientific officer.

  • Dr Michael Watson appointed as president of Valera Dr Michael Watson appointed as president of Valera

    Former Sanofi Pasteur policy head joins Moderna Therapeutics firm. Valera, one of Moderna Therapeutics' venture companies, has appointed Dr Michael Watson as its new president. ... Moderna's technology, coupled with its goal to deliver transformative

More from appointments
Approximately 3 fully matching, plus 5 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Quick links

Infographics

Multimedia